News • Green light for trial study

Blood plasma from recovered COVID-19 patients: a promising approach

In a small clinical trial just granted approval, about 30 COVID-19 patients at Karolinska University Hospital may soon begin to receive blood plasma from people who have recovered from the disease.

Image by Gerd Altmann from Pixabay

Sweden's Ethical Review Authority has approved the trial treatment, and its effectiveness will be evaluated in a study by researchers at Karolinska Institutet and the Karolinska University Hospital. Using blood plasma from people who have recovered from a viral infection to treat those still sick is a common practice that has been tried against almost every new epidemic since the Spanish flu in the early 20th century. According to Joakim Dillner, professor of infectious disease epidemiology at Karolinska Institutet, the therapy has had some effect on about half of all infections against which it has been tried in the last century. "We don't know if it will work against COVID-19 but since it has worked on so many other infections, we have to try," says Joakim Dillner, who is leading the study.

Photo
Donated blood from recovered coronavirus patient may hold the key to fighting COVID-19

Credit: Karolinska Institutet

One of the advantages of the treatment is that the logistics around blood donations is already in place at Blodcentralen. One of the disadvantages is that a method to measure antibody levels against COVID-19 in the blood plasma is not fully developed yet. Here, researchers at Karolinska Institutet, who are working to develop relevant antibody tests, will play a big role. "There are a lot of people at KI and SciLifeLab who are eager to help and are working to improve methods to test antibody levels in the blood after COVID-19 infection," Joakim Dillner says. "We need these analyses to determine which of the recovered patients may be suitable as blood donors."

Both blood donations and plasma transfusions are of course voluntary. In a first step, the safety of the practice is analyzed with 10 patients who are admitted to Karolinska University Hospital with COVID-19 and who can actively participate by answering questions. If the treatment is deemed safe, the study will expand to test its effect on another 20 patients.

According to Joakim Dillner, it is only recovered COVID-19 patients previously treated in Stockholm who may donate blood at this time. This is because during other epidemics, different strains of the virus have popped up in different regions, and it is important to find blood donors who have had the same variant of the virus as those who are still ill.

Recommended article

It is like a one-time treatment during a crucial phase where you need help to fight the infection

Joakim Dillner

Previous experiences of similar treatments against other infections suggest that a dose of up to 200 ml plasma may suffice to reduce symptoms. That would imply that a standard donation of 600 ml plasma from a COVID-19 survivor with usable plasma may be enough to treat three patients, according to Joakim Dillner. "It is like a one-time treatment during a crucial phase where you need help to fight the infection," he says. "Then you can get a little boost from someone else who has managed to beat it." Risks associated with the treatment are the same as for all blood transfusions and include allergic reactions, among others.


Source: Karolinska Institutet

03.04.2020

Read all latest stories

Related articles

Photo

News • Coronavirus infection

Hair and libido loss: list of 'Long Covid' symptoms grows

Long Covid sufferers have experienced a wider set of symptoms than previously thought including hair loss and sexual dysfunction, new research has found.

Photo

News • Betacoronavirus protection

Nanoparticle vaccine protects against Covid-19 variants and related viruses

A new type of vaccine provides protection against a variety of SARS-like betacoronaviruses, including SARS-CoV-2 variants, in mice and monkeys, according to a new study.

Photo

News • Breakthrough with the help of computer-based protein design

Immune diseases: Advancing the development of novel drugs

Latest developments in computational protein design enable the simulation of sequence and structural changes in proteins for creating novel agents in human medicine.

Related products

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – Early Sepsis Indicator

Blood Cell Counter

Beckman Coulter – Early Sepsis Indicator

Beckman Coulter Diagnostics
Subscribe to Newsletter